Company profile

FEops

AI-powered predictive simulation for structural heart interventions

Cardiology & Cardiovascular Health

Company profile

About FEops

FEops is a medical technology company specializing in AI-powered predictive simulation solutions for structural heart interventions. The company's flagship product, FEops HEARTguide™, is a cloud-based procedure planning platform specifically developed for interventional cardiologists to plan percutaneous procedures quickly and accurately. The platform combines finite element simulation technology with AI-based anatomical analysis to deliver predictive insights that improve procedural outcomes. FEops HEARTguide™ enables physicians to select optimal device sizes and implant positions by predicting device apposition, frame deformation, and compression rates for specific patient anatomies. The platform provides semi-automatic identification and measurement of anatomical landmarks through its DICOM interface, along with 3D visualization and image reconstruction capabilities. Clinical workflows are available for Left Atrial Appendage Occlusion (LAAO), Transcatheter Aortic Valve Implantation (TAVI), and Transcatheter Mitral Valve Replacement (TMVR). The platform has demonstrated clinically proven results, including a 15% reduction in closure devices used and a twofold increase in procedural success rates in the PREDICT-LAA study. In the PRECISE-TAVI study, 35% of pre-procedural decisions were changed using the platform, resulting in favorable clinical outcomes. FEops HEARTguide™ serves interventional cardiologists, medical care providers, and researchers, offering secure collaborative features for case sharing with peers and industry partners. The company continues to innovate with new features for TAVI lifetime management and future valve-in-valve procedures.

Company description FEops official website

Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at FEops?

Claim this profile to manage Company information and connect with the Health AI Central audience.

Claim this listing

01 · Operating footprint

Where the Company operates

Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.

Clinical focus

  • Bicuspid Aortic Valve (BAV)
  • Left Atrial Appendage Occlusion (LAAO)
  • Mitral Annulus Calcification (MAC)
  • Transcatheter Aortic Valve Implantation (TAVI)
  • Transcatheter Mitral Valve Replacement (TMVR)

Who it serves

  • Health systems
  • Interventional cardiologists
  • Medical care providers
  • Researchers

Deployment & integration

Cloud Saas deployment with recorded integration context.

Geographic context

MarketsNot currently listed
Company sourceOfficial website

Company milestones

Platform expansion

New collaborative platform feature enabling secure case sharing with peers and industry partners. TAVI lifetime management features including redo-TAVI options with coronary access insights and leaflet overhang evaluation. Expanded simulation outputs for skirt apposition and conduction system contact assessment.

Partnerships

Recorded partners

  • Abbott (Amplatzer Amulet devices)
  • Boston Scientific (WATCHMAN FLX devices)
  • Medtronic (Evolut FX+ devices)

02 · Flagship portfolio

Products, workflows, and platform capabilities

Selected source-backed Company products and the available commercial context.

FEops HEARTguide

AI-powered predictive simulation platform for structural heart intervention planning

Platform · Cloud SaaSCompany source

FEops HEARTguide LAAO Workflow

Predictive simulation for Left Atrial Appendage Occlusion procedures

Software · Cloud SaaSCompany source

FEops HEARTguide TAVI Workflow

Transcatheter Aortic Valve Implantation planning with lifetime management

Software · Cloud SaaSCompany source

FEops HEARTguide TMVR Workflow

Early-stage simulation technology for Transcatheter Mitral Valve Replacement

Software · Cloud SaaSCompany source

03 · Research intelligence

Research Intelligence evidence

Publications, preprints, clinical validation, and regulatory records in Evidence Position order.

Evidence position

Publications, clinical validation, and regulatory records connected to this Company appear here.

04 · Company-reported outcomes

Outcomes and case studies

Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.

15% reduction in total number of closure devices used

PREDICT-LAA study for LAAO procedures

Twofold increase in procedural success with single device and deployment

PREDICT-LAA study (+90 days follow-up)

35% of pre-procedural decisions changed

PRECISE-TAVI study, resulting in favorable clinical outcomes

PREDICT-LAA Study

Improving efficiency and outcomes of LAAO procedures through predictive simulation

15% reduction in total number of closure devices used; twofold increase in procedural success with single device and deployment (+90 days)

PRECISE-TAVI Study

Optimizing pre-procedural decision-making for TAVI procedures

35% of pre-procedural decisions were changed, resulting in favorable clinical outcomes

05 · Leadership

Leadership team

Leadership profiles and professional links from the current Company record.

No active leadership profiles are currently listed.

06 · Company updates

Updates from FEops

Recent articles published on FEops's official website.

No Company updates are currently listed.

07 · HAIC coverage

Coverage and analysis

Health AI Central reporting that mentions this Company.

No HAIC coverage is currently linked to this Company.

08 · Official presence

Company sources and channels

Curated official destinations from the active Company record.

09 · Market pathway

Additional Companies in this Market

Other active Companies in the same market, selected alphabetically from the HAIC directory.

Market context

Cardiology & Cardiovascular Health

Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.

Explore the full market directory or compare this Company with additional active profiles.

View all Companies in this market

10 · Pro research

Coming soon

Expanded Company research is in development.

Health AI Central Pro · Coming Soon

Deeper Company research is coming soon.

Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.

ResearchEvidence analysis

Linked research, clinical, and regulatory source pathways.

CompanyTechnical context

Expanded product, deployment, integration, and partnership research.

MethodSource & review record

Record-level provenance and review context.

Coming Soon